Aberrant expression or dysfunction of VMP1 has been reported in various pathological conditions—including neurodegenerative disorders like Parkinson’s disease (PD), as well as pancreatitis, hepatitis, and cancer—highlighting its potential as a promising therapeutic target [30–32]. This evidence concerns the gene VMP1 and pancreatitis.